AstraZeneca PLC (NYSE:AZN) investors received a reassuring earnings report at a sensitive point in the company’s growth story ...
UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter. The deal could create ...
Stocktwits on MSN
AstraZeneca-Bristol Myers’ $400B merger buzz cools after report denies talks – 'There never was a deal to be done'
The update follows an earlier report from the Financial Times, which said the companies had been in discussions for several months over a potential merger. ・According to Semafor, a merger could shift ...
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff ...
AstraZeneca declined to comment, while Bristol Myers Squibb did not immediately respond to CNBC's request for comment outside ...
The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion. Read more at straitstimes.com. Read more at straitstimes.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results